At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
TK1258drug
Likely dose
TK1258 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma
In Brief
A Phase 2 clinical trial evaluating TK1258 for Prostate Cancer. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones. Researchers also want to learn how changes in your blood PSA level might affect the rebuilding of healthy bones while you are being treated with TKI258 for prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartApr 2010
Primary CompletionJun 2017
TodayJul 2026
First PostedJan 29, 2009
Enrollment StartApr 7, 2010
Primary CompletionJun 12, 2017
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 17.4 years ago
Interventions
TK1258drug
4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).